

Alexander Gerhard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6258057/publications.pdf>

Version: 2024-02-01

44
papers

3,282
citations

331538

21
h-index

254106

43
g-index

46
all docs

46
docs citations

46
times ranked

4861
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. <i>Neurobiology of Disease</i> , 2006, 21, 404-412. | 2.1 | 982 |
| 2 | Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2018, 83, 61-69. | 0.7 | 266 |
| 3 | Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. <i>NeuroImage</i> , 2005, 24, 591-595. | 2.1 | 235 |
| 4 | Reference and target region modeling of [11C]-(R)-PK11195 brain studies. <i>Journal of Nuclear Medicine</i> , 2007, 48, 158-67. | 2.8 | 216 |
| 5 | Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156. | 4.9 | 175 |
| 6 | Brain inflammation is induced by co-morbidities and risk factors for stroke. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1113-1122. | 2.0 | 173 |
| 7 | Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [¹¹ C]-(R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010, 25, 97-107. | 2.2 | 163 |
| 8 | In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. <i>Movement Disorders</i> , 2006, 21, 89-93. | 2.2 | 162 |
| 9 | In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. <i>Movement Disorders</i> , 2004, 19, 1221-1226. | 2.2 | 128 |
| 10 | 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 503-511. | 3.3 | 109 |
| 11 | Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377. | 4.5 | 94 |
| 12 | TSPO imaging in parkinsonian disorders. <i>Clinical and Translational Imaging</i> , 2016, 4, 183-190. | 1.1 | 56 |
| 13 | [11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1406-1419. | 3.3 | 55 |
| 14 | Microglial activation, white matter tract damage, and disability in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e443. | 3.1 | 51 |
| 15 | Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2831-2847. | 3.3 | 45 |
| 16 | Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194. | 2.8 | 42 |
| 17 | Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 564-568. | 2.2 | 41 |
| 18 | Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514. | 0.4 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983. | 0.4 | 31 |
| 20 | Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646. | 1.4 | 28 |
| 21 | A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817. | 3.7 | 27 |
| 22 | Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984. | 0.9 | 25 |
| 23 | Frontotemporal lobar degeneration and social behaviour: Dissociation between the knowledge of its consequences and its conceptual meaning. <i>Cortex</i> , 2017, 93, 107-118. | 1.1 | 22 |
| 24 | Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum τ and pNfH : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47. | 2.8 | 21 |
| 25 | Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 527-532. | 1.1 | 18 |
| 26 | Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771. | 0.9 | 12 |
| 27 | Functional neuroanatomical associations of working memory in early-onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 176-184. | 1.3 | 10 |
| 28 | A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79. | 4.4 | 9 |
| 29 | Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 405. | 2.0 | 8 |
| 30 | Altered network stability in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2021, 107, 109-117. | 1.5 | 8 |
| 31 | Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168. | 0.9 | 7 |
| 32 | Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-26. | 0.9 | 5 |
| 33 | Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, . | 1.5 | 5 |
| 34 | Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10. | 3.0 | 4 |
| 35 | Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167. | 1.5 | 3 |
| 36 | An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Does increased microglial activation lead to faster progression in PSP?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 685-685. | 0.9 | 1 |
| 38 | Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339. | 0.9 | 1 |
| 39 | Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591. | 2.4 | 1 |
| 40 | Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , . | 1.5 | 1 |
| 41 | Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332. | 1.8 | 1 |
| 42 | The <sc>CBIâ€R</sc> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658. | 1.7 | 1 |
| 43 | Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 1 |
| 44 | A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |